This study is assessing the benefit of using a type of local ablative therapy (which could include surgery or radiation therapy) on top of standard of care treatment for people with colorectal cancer.
This trial is treating patients with metastatic colorectal caner.
This is a surgical, systemic therapy and radiation therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Randomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group (AGITG)
Other Non-Commercial Sponsor
Cancer Council Victoria
Eligible participants will be randomly allocated to either the local ablative therapy (LAT) arm, or the control arm. In the LAT arm, participants will receive metastasis-directed LAT such as radiation therapy or thermal ablation following initial standard first-line systemic treatment. In the control arm, participants will receive continued first-line systemic treatment alone. Those receiving LAT will return to systemic treatment 16 weeks post-randomisation.
Recruiting Hospitals Read More